CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2010-04-16): Gilead drug effective against liver disease: study

Drug & Device Development

Gilead drug effective against liver disease: study

Last Updated: 2010-04-16 18:37:14 -0400 (Reuters Health)

LOS ANGELES (Reuters) - Gilead Sciences Inc's experimental drug, GS-9450, was shown in a mid-stage trial to improve markers of liver damage in patients with non-alcoholic steatohepatitis.

Researchers said the phase II trial, involving 124 patients, showed treatment with the drug reduced levels of alanine (ALT) and aspartate aminotransferases (AST)

The results were presented on Friday in Vienna at the International Liver Congress.

GS-9450 is a caspase inhibitor designed to block proteins that initiate apoptosis in damaged cells.

Gilead said the drug is a potential new treatment option for patients with non-alcoholic steatohepatitis.

Further studies are needed to evaluate the drug's efficacy and safety in larger patient populations.

The trial showed that, after four weeks, 35% of patients treated with the highest dose of GS-9450 achieved ALT levels within the normal range. Forty-eight percent achieved normal levels of AST. Placebo treatment showed no meaningful change for either enzyme.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.